Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis

@article{Serretti2009TreatmentEmergentSD,
  title={Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis},
  author={Alessandro Serretti and Alberto Chiesa},
  journal={Journal of Clinical Psychopharmacology},
  year={2009},
  volume={29},
  pages={259-266}
}
Background: Sexual dysfunction (SD) is an important underestimated adverse effect of antidepressant drugs. Patients, in fact, if not directly questioned, tend to scarcely report them. The aim of the present meta-analysis was to quantify SD caused by antidepressants on the basis of studies where sexual functioning was purposely investigated through direct inquiry and specific questionnaires. Methods: A literature search was conducted using MEDLINE, ISI Web of Knowledge, and references of… Expand
Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period
TLDR
Improved recognition and management of TESD may improve quality of life for MDD patients in usual clinical practice, with greater MDD effectiveness in favour of duloxetine. Expand
Sexual Dysfunction Related to Non-SSRI Second Generation Antidepressants: A Meta-Analysis
Objective: This systematic review is aimed to quantitatively summarise the prevalence of sexual dysfunction among non-SSRI second generation antidepressants namely agomelatine, bupropion, duloxetine,Expand
A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study
TLDR
Despite being a well-known, long-standing side effect of antidepressants, sexual dysfunction continues to be extremely common in patients receiving antidepressants, especially serotonergic ones, potentially jeopardizing treatment success in a substantial proportion of patients. Expand
ANTIPSYCHOTICS AND SEXUAL DYSFUNCTION: EPIDEMIOLOGY, MECHANISMS AND MANAGEMENT
Objective: Growing attention has recently been given to the sexual dysfunction (SD) burden related to antipsychotics. The aims of the present work are 1) to review current evidence about SD relatedExpand
Sexual dysfunction and antidepressants: a review with emphasis on treatment
TLDR
Although SD is an important adverse effect of antidepressant medication, patients tend to be reluctant to report them if not directly questioned, which suggests that consideration of the doctor-patient relationship is needed when deciding on an appropriate treatment plan. Expand
Sexual dysfunction related to psychotropic drugs: a critical review--part I: antidepressants.
TLDR
There is consistent evidence to suggest that antidepressant medication adversely affects one or more of the 3 phases of sexual response (desire, arousal and orgasm) and Clinicians must be aware of drug-induced sexual dysfunction. Expand
Assessment and management of sexual dysfunction in the context of depression
TLDR
A concise, evidence-based schematic is presented to assist physicians in minimizing treatment-emergent sexual dysfunction (TESD) while treating depression. Expand
Sexual dysfunction during long-term treatment with antidepressants in unipolar disorder: clinical and management aspects
Summary Objective Major depression is a chronic condition. Treatment with antidepressants is often stopped due to long-term side effects. Antidepressants are frequently associated with sexualExpand
A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics
TLDR
It is found that significant differences exist across different antipsychotics in terms of total SD, such as quetiapine, ziprasidone, perphenazine, and aripiprazole were associated with relatively low SD rates, whereas olanzapine and risperidone are associated with higher SD rates. Expand
Antidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications
TLDR
A review of articles published within the last 10 years on sexual dysfunction and depression in adults, with an emphasis on the relationship of treatments for depression on SD, to aid physicians in the multidisciplinary approach to treating patients with SD and depression. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 82 REFERENCES
Sexual dysfunction during antidepressant treatment.
TLDR
The relatively high incidence of sexual dysfunction associated with antidepressant treatment in this systematic study emphasizes the importance of a detailed inquiry about sexual side effects as this interferes with treatment compliance. Expand
Effects of SSRIs on sexual function: a critical review.
TLDR
The effects of SSRIs on sexual functioning seem strongly dose-related and may vary among the group according to serotonin and dopamine reuptake mechanisms, induction of prolactin release, anticholinergic effects, inhibition of nitric oxide synthetase, and propensity for accumulation over time. Expand
Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients.
TLDR
All three antidotes were found to be safe and relatively effective, although yohimbine was significantly more effective than amantadine or cyproheptadine in reversing SRI-induced sexual dysfunction. Expand
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
TLDR
Open-ended questions are an insufficient tool to estimate sexual dysfunction, and premarketing clinical trials should therefore include basic explicit assessments, and the failure to find a correlation between treatment duration and sexual dysfunction adds to the notion that sexual side effects due to SSRIs do not abate over time. Expand
Male Sexual Side Effects Associated with Antidepressants: A Descriptive Clinical Study of 32 Patients
  • Jeffrey H. Hsu, Winston W. Shen
  • Psychology, Medicine
  • International journal of psychiatry in medicine
  • 1995
TLDR
Male sexual side effects can occur randomly and involve any sexual phase randomly, and the treatment approaches are similar, regardless of the types of sexual dysfunction associated with antidepressants. Expand
Prevalence of sexual dysfunction among newer antidepressants.
TLDR
This is the first study to assess sexual dysfunction across the newer antidepressants using consistent methodology and a validated rating scale and overall, SSRIs and venlafaxine XR were associated with higher rates of sexual dysfunction than bupropion or nefazodone. Expand
Female Sexual Side Effects Associated with Selective Serotonin Reuptake Inhibitors: A Descriptive Clinical Study of 33 Patients
  • Winston W. Shen, Jeffrey H. Hsu
  • Psychology, Medicine
  • International journal of psychiatry in medicine
  • 1995
TLDR
It is suggested that SSRI-associated female sexual dysfunction occurs at a higher rate than previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion. Expand
Fluoxetine-induced sexual dysfunction and an open trial of yohimbine.
  • F. M. Jacobsen
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 1992
TLDR
It is suggested that fluoxetine-induced sexual dysfunction may include decreased sexual desire as well as decreased physical functioning and may occur more frequently than previously appreciated and fluoxete-inducedSexual dysfunction may be treatable with yohimbine. Expand
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
TLDR
The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine. Expand
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
TLDR
Regardless of treatment, patients who achieved remission of MDD showed improvement in global sexual functioning, whereas worsening was observed for patients who did not achieve remission (P < 0.001). Expand
...
1
2
3
4
5
...